AgomAb Therapeutics is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues. In April 2019, a 21 million euros financing round was raised. Prior to AgomAb Therapeutics, Tim was VP Corporate Development at AM-Pharma where he was responsible for Corporate and Business Development of the company. In that capacity he co-led the $600M option-to-acquisition deal between Pfizer and AM-Pharma. Prior to that, Tim was a senior associate at Aescap Venture, a venture capital fund investing in European medical companies, where he was instrumental in the financing and support of various portfolio companies. Tim holds an executive MBA from IMD (Switzerland), where he was named Valedictorian, and gained a Science and Innovation Masters and a Drug Innovation Masters, both with honors from Utrecht University (NL).
Harvard Business Case
Jumpstart your career
Join BioBusiness Summer School to jumpstart your career in Life Sciences by gaining knowledge of business aspects such as product development, IPR, finance and business models. The next edition of the summer school will be organised from 24-28 June 2019 in Amsterdam, the Netherlands.
The BioBusiness Summer School is a programme tailored to bridge the gap. By immersing yourself in the business aspects of Life Sciences during this programme, you will learn the basic knowledge of BioBusiness, gain insight in the world of Life Sciences companies, meet leading business leaders and increase your international network.